PDCD1 and Alzheimer disease: Emerging studies suggest that inhibiting PD1 signaling can improve clearance of cerebral Aβ plaques, cognitive performance and enhance peripheral immune responses (Baruch et al. 2016; Deczkowska and Schwartz 2018), supporting the hypothesis that targeting exhausted T cells could represent a viable treatment option for AD.